Lab
Aspirus Wausau Hospital, INC
Aspirus Wausau Hospital, INC was paid $6.93M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 30% of everything it billed.
33Billing provider infoASPIRUS WAUSAU HOSPITAL, INC
WAUSAU, WI 54401
WAUSAU, WI 54401
33aNPI1821115023assigned 03/23/2007
33bProvider typeClinical Medical Laboratory
28Total paid$6.93M
24GClaims376,252
24DCodes billed147
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Wisconsin
Rank by total paid#9 of 75
Median peer was paid$106K
This provider vs. median65×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,356 | $329K | |
| 2019 | 40,501 | $593K | |
| 2020 | 48,920 | $1.07M | |
| 2021 | 80,094 | $1.85M | |
| 2022 | 82,501 | $1.63M | |
| 2023 | 57,749 | $780K | |
| 2024incomplete | 44,131 | $671K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 30% | 28,143 | 24,176 | $2.08M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.8% | 3,509 | 2,767 | $404K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.4% | 10,496 | 9,417 | $304K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.3% | 10,380 | 9,308 | $300K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.9% | 20,966 | 17,767 | $273K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.8% | 11,618 | 10,355 | $266K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.2% | 16,825 | 14,995 | $220K |
| 87070 | 3.1% | 27,472 | 25,437 | $217K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.5% | 1,466 | 1,333 | $175K |
| 81514 | 2.0% | 1,021 | 862 | $137K | |
| 80061 | Lipid panel | 2.0% | 13,730 | 12,511 | $137K |
| 87653 | 1.8% | 4,255 | 3,934 | $126K |
135 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.6% | 621 | $113K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.5% | 6,046 | $105K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.5% | 15,920 | $103K |
| 87505 | 1.5% | 1,009 | $103K | |
| 80081 | 1.2% | 5,607 | $83K | |
| 80053 | Comprehensive metabolic panel | 1.1% | 9,075 | $76K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.1% | 1,471 | $75K |
| 86803 | 1.1% | 6,573 | $74K | |
| 87088 | 1.0% | 11,317 | $71K | |
| 84403 | <1% | 2,832 | $61K | |
| 82607 | <1% | 4,385 | $54K | |
| 87077 | <1% | 7,602 | $52K | |
| 80074 | <1% | 1,549 | $51K | |
| 84702 | <1% | 4,296 | $49K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,749 | $48K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,080 | $41K |
| 87186 | <1% | 5,696 | $41K | |
| 87660 | <1% | 2,477 | $39K | |
| 87480 | <1% | 2,475 | $39K | |
| 86618 | <1% | 2,859 | $38K | |
| 82746 | <1% | 3,137 | $37K | |
| 86480 | <1% | 788 | $36K | |
| 87510 | <1% | 2,475 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,370 | $35K |
| 82728 | <1% | 3,232 | $35K | |
| 84153 | <1% | 2,205 | $34K | |
| 84270 | <1% | 1,701 | $30K | |
| 84439 | <1% | 4,178 | $30K | |
| 84481 | <1% | 2,191 | $29K | |
| 80306 | <1% | 2,003 | $29K | |
| 82670 | <1% | 1,234 | $28K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,655 | $26K |
| 86762 | <1% | 2,895 | $26K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,924 | $26K |
| 82043 | <1% | 5,189 | $25K | |
| 85027 | <1% | 5,014 | $25K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 598 | $24K |
| 83550 | <1% | 3,538 | $24K | |
| 87340 | <1% | 3,594 | $23K | |
| 80050 | General health panel | <1% | 1,269 | $23K |
| 81001 | <1% | 8,638 | $22K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 590 | $19K |
| 83540 | <1% | 3,744 | $19K | |
| 86039 | <1% | 2,154 | $19K | |
| 83655 | <1% | 2,366 | $17K | |
| 86592 | <1% | 5,252 | $16K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 604 | $16K |
| 83970 | <1% | 424 | $14K | |
| 84146 | <1% | 833 | $13K | |
| 87328 | <1% | 1,176 | $13K | |
| 86140 | <1% | 3,097 | $13K | |
| 83001 | <1% | 806 | $12K | |
| 86769 | <1% | 365 | $10K | |
| 83735 | <1% | 1,930 | $10K | |
| 82784 | <1% | 1,591 | $9K | |
| 87329 | <1% | 1,144 | $9K | |
| 84144 | <1% | 571 | $9K | |
| 87205 | <1% | 2,346 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 86 | $8K |
| 86364 | <1% | 819 | $8K | |
| 85610 | <1% | 2,283 | $7K | |
| 82950 | <1% | 1,871 | $7K | |
| 85018 | <1% | 3,621 | $7K | |
| 86431 | <1% | 1,376 | $6K | |
| 85049 | <1% | 1,709 | $6K | |
| 84436 | <1% | 1,083 | $6K | |
| 86706 | <1% | 705 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 139 | $5K |
| 87338 | <1% | 351 | $4K | |
| 81025 | <1% | 554 | $4K | |
| 83880 | <1% | 138 | $4K | |
| 87807 | <1% | 305 | $4K | |
| 83002 | <1% | 240 | $4K | |
| 85014 | <1% | 1,822 | $3K | |
| 86850 | <1% | 1,430 | $3K | |
| 82533 | <1% | 282 | $3K | |
| 87075 | <1% | 406 | $3K | |
| 83690 | <1% | 474 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,178 | $3K |
| 87631 | <1% | 22 | $3K | |
| 85652 | <1% | 1,161 | $2K | |
| 87210 | <1% | 473 | $2K | |
| 82570 | <1% | 490 | $2K | |
| 80076 | <1% | 293 | $2K | |
| 85007 | <1% | 715 | $2K | |
| 86376 | <1% | 169 | $2K | |
| 86665 | <1% | 196 | $2K | |
| 87493 | <1% | 32 | $2K | |
| 86787 | <1% | 298 | $1K | |
| 87046 | <1% | 510 | $1K | |
| 84156 | <1% | 482 | $1K | |
| 84460 | <1% | 321 | $1K | |
| 86900 | <1% | 1,083 | $1K | |
| 80197 | <1% | 110 | $1K | |
| 86901 | <1% | 1,084 | $1K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 48 | $1K |
| 88307 | <1% | 80 | $1K | |
| 83718 | <1% | 144 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 57 | $943.34 |
| 86663 | <1% | 109 | $906.84 | |
| 87147 | <1% | 213 | $886.50 | |
| 86664 | <1% | 88 | $876.52 | |
| 83516 | <1% | 229 | $851.09 | |
| 87468 | <1% | 40 | $779.64 | |
| 87484 | <1% | 39 | $736.89 | |
| 87469 | <1% | 39 | $736.89 | |
| 82465 | <1% | 189 | $727.85 | |
| 84165 | <1% | 78 | $727.82 | |
| 86258 | <1% | 84 | $661.37 | |
| 84550 | <1% | 196 | $651.68 | |
| 83993 | <1% | 32 | $612.24 | |
| 86644 | <1% | 58 | $561.79 | |
| 83721 | <1% | 77 | $540.19 | |
| 84450 | <1% | 123 | $505.52 | |
| 85060 | <1% | 130 | $371.79 | |
| 88304 | <1% | 25 | $309.95 | |
| 86645 | <1% | 56 | $300.90 | |
| 88342 | <1% | 22 | $261.99 | |
| 82947 | <1% | 83 | $234.90 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 15 | $228.48 |
| 82565 | <1% | 50 | $163.84 | |
| 80164 | <1% | 12 | $158.00 | |
| 86696 | <1% | 12 | $156.36 | |
| 80178 | <1% | 14 | $124.32 | |
| 82247 | <1% | 40 | $116.46 | |
| 84703 | <1% | 19 | $113.10 | |
| 86695 | <1% | 12 | $106.56 | |
| 82977 | <1% | 13 | $89.78 | |
| 82150 | <1% | 14 | $78.02 | |
| 83615 | <1% | 15 | $66.56 | |
| 82248 | <1% | 19 | $65.26 | |
| 82040 | <1% | 19 | $64.35 | |
| 81003 | <1% | 29 | $48.15 | |
| 85730 | <1% | 15 | $48.08 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 63 | $18.77 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Parent organizationASPIRUS WAUSAU HOSPITAL, INC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.